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How promising is phototherapy for cancer?
Huayun Shi 1 and Peter J. Sadler 1
Oncological phototherapy, including current photodynamic therapy (PDT), developmental photoactivated chemotherapy (PACT)
and photothermal therapy (PTT), shows promising photo-efficacy for superficial and internal tumours. The dual application of light
and photochemotherapeutic agents allows accurate cancer targeting, low invasiveness and novel mechanisms of action. Current
advances in new light sources and photoactive agents are encouraging for future development.
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MAIN
Light was first applied 4000 years ago in ancient Egypt to treat
vitiligo, but the modern clinical usage of anticancer photodynamic
therapy (PDT) began at the Roswell Park Cancer Institute in the
1970s. Efficacy switched-on by irradiation makes the treatment
highly controllable, spatially and temporally with minimal inva-
siveness. In current clinical PDT, photosensitisers excited by light
generate cytotoxic radicals by interaction with biomolecules (Type
I pathway), or, in the Type II pathway, convert ground-state oxygen
(3O2) directly into highly reactive cytotoxic excited-state singlet
oxygen (1O2).
1 PDT can not only kill cancer cells directly, but also
cause vascular damage that impedes tumour oxygen supply.
Photosensitisers are key components of PDT (Fig. 1, Table 1). An
ideal photosensitiser shows low dark cytotoxicity, tumour-specific
accumulation, high photocytotoxicity, low skin photosensitivity
and facile administration.1,2 The first-generation photosensitiser
Photofrin®, a mixture of oligomeric haematoporphyrin derivatives
(HpD), was approved to treat bladder cancer with red light (630
nm) in 1993 in Canada, and remains the most widely used
photosensitiser, despite its poor cancer selectivity, low red-light
absorption and long-term photosensitivity. 5-Aminolevulinic acid
(Levulan®), a key precursor for biosynthesis of protoporphyrin IX,
and its derivative methyl aminolevulinate (Metvix®), are readily
synthesised in high purity, and approved by the FDA as second-
generation photosensitisers. Peripheral double backbone reduc-
tion of porphyrin photosensitisers can red-shift and strengthen
their longest-wavelength absorbance. Thus, chlorin derivatives
Foscan®, Radachlorin® and Laserphyrin® have been approved for
clinical PDT with red light (ca. 660 nm), and bacteriochlorin
derivative Redaporfin, in clinical Phase 2, can be activated with
infrared light (749 nm).
Metal complexes offer potential advantages in the design of
photosensitisers, since the metal can improve stability and
photocytotoxicity, and allow their quantification and localisation
by for exmaple ICP-MS.2 Also, with the help of advanced mass
spectrometry, the molecular effects of metal-based photosensi-
tisers on biochemical pathways in cancer cells can be probed
effectively.2 Vascular-targeted Tookad® Soluble is a Pd(II)-bacter-
iopheophorbide approved in the EU to treat localised prostate
cancer with near-infrared (NIR) irradiation (753 nm). A Sn(IV)-
chlorin derivative Purlytin is in Phase 2/3 trials for cutaneous
metastatic breast cancer, and TLD-1433, a polypyridyl Ru(II)
complex, has entered clinical trials for non-muscle-invasive
bladder cancer (NMIBC).3
The excitation wavelengths of photosensitisers are restricted by
their absorption spectra and affect light tissue penetration that
varies in different organs. Usually, PDT is performed at wave-
lengths >620 nm, since longer wavelength light penetrates more
deeply.3,4 However, for superficial tumours (e.g. NMIBC), green
light may be more effective and able to circumvent unwanted side
effects on healthy tissue. In addition, pain and discomfort caused
by red-light PDT can be significantly reduced using daylight PDT
to treat precancerous skin lesions.5 Daylight skin PDT can be
performed using sunlight (>4–8 J/cm2), but light devices are
necessary for internal tumours, and for skin cancer in poor
sunlight.4 Lasers as PDT light sources offer high power output and
easy connection to optical fibres and endoscopes, with precise
light delivery to tumours in internal organs. However, due to the
narrow spectral width, small beam cross-section, cost and
handling requirements of lasers, broadband lamps with specific
filters are usually preferred to treat large superficial lesions directly
(e.g. non-melanoma skin cancer). Cheap and compact light
emitting diodes (LEDs) have become the mainstream light sources
for skin PDT with a wide wavelength range, adjustable power
output and large irradiation areas. Two-photon PDT using
femtosecond solid-state lasers allows spatially precise activation
of photosensitisers in tissues with for example 350 nm UVA using
more deeply penetrating 700 nm red-light pulses. This may be
clinically useful if methods can be developed for fast rastering of
the very small (ca. 1 µm) laser spot so that reasonable tumour
volumes can be treated in a short time.
Drug administration is another practical issue for clinical PDT.1,3
Intravenous injection is the traditional systemic administration for
Photofrin® and other tetrapyrrolic photosensitisers. Although it is
convenient and efficient for internal organ PDT, high tumour-
specific accumulation of photosensitisers is required to improve
efficacy and reduce systemic cytotoxicity. By contrast, 5-
aminolevulinic acid can be applied topically and orally. For
treatment of large areas topically, drugs should have low
photocytotoxicity to normal tissue. TLD-1433 is intravesically
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instilled and relies on high selectivity for bladder tumours over
normal tissues.
Despite the wide clinical applications of PDT, it suffers from
several problems. Firstly, the mechanism of action is highly
dependent on oxygen, which limits the efficacy of PDT in hypoxic
tumours. However, oxygen-independent photosensitisers are now
becoming available (Fig. 1). For example, a highly oxidative
organo-Ir(III) photosensitiser can catalyse the photoreduction of
cytochrome c synergistically with NADH oxidation under hypoxia,
and is phototoxic towards both normoxic and hypoxic cancer
cells.6 In another strategy, a chlorin photosensitiser has been
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Fig. 1 a FDA-approved anticancer photosensitisers; b metal-based photoactive anticancer complexes under development.
Table 1. PDT agents in clinical use or in clinical trialsa.
Class PDT agent Metal Stage Excitation (nm) Area Cancer type
Protoporphyrin IX
precursor
5-Aminolevulinic acid (Levulan®) FDA approved 635 Global Skin, brain, oesophagus
Methyl aminolevulinate (Metvix®) FDA approved 635 Skin
Hexyl 5-aminolevulinate (Hexvix®) FDA approved 380–450 (diagnosis) Bladder
Porphyrin derivatives Porfimer sodium (Photofrin®) FDA approved 630 Global Lung, bladder, oesophagus,
bile duct, brain
Photogem MHRF approved 660 Russia Respiratory and digestive
tracts, urogenital
Chlorin derivatives Temoporfin (Foscan®) EMA approved 652 EU Head and neck, bile duct, lung
Ce6-PVP (Fotolon®) Phase 2 660–670 Germany Lung
Radachlorin® MHRF approved 662 Russia Skin
Talaporfin sodium (Laserphyrin®) MHLW approved 664 Japan Lung, brain
HPPH (Photochlor®) Phase 2 665 USA Lung, oral cavity, oesophagus
Bacteriochlorin
derivatives
Redaporfin Phase 2 749 Portugal Head and neck
Phthalocyanine
derivatives
Silicon phthalocyanine (Pc4) Phase 1 672 USA Skin
Metal complex Padoporfin (TOOKAD®) Pd Terminated 763 EU Prostate
Padeliporfin potassium (TOOKAD®
Soluble)
Pd EMA approved 753 EU Prostate
TLD-1433 Ru Phase 2 520 Canada Bladder, brain
Motexafin lutetium (Antrin®) Lu Terminated 732 USA Breast, prostate
Rostaporfin (Purlytin®) Sn Phase 2/3 664 USA Breast, bile duct,
ovarian, colon
aData from clinicaltrials.gov.
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(Ce6-PEG-Pt(IV) conjugate) in upconverting nanoparticles that
exhibit dramatically enhanced photocytotoxicity in hypoxic
tumour models with NIR (980 nm) irradiation.7 Diazido Pt(IV)
complexes themselves show potential for a novel form of
photoactivated chemotherapy (PACT). They are highly stable in
the dark but decompose upon irradiation with visible light to
release cytotoxic azidyl radicals and reactive oxygen species, as
well as DNA-binding Pt(II) species.8 Axial derivatisation of diazido
Pt(IV) complexes with anticancer drugs or cancer-targeting vectors
can improve the photo-selectivity of the agents and red-shift their
activation wavelength.
Cancer-targeting proteins can assist the delivery of photosensi-
tisers to tumours and increase selectivity versus normal tissue. For
example, Rutherrin, a conjugate of TLD-1433 and apo-transferrin,
exhibits enhanced cancer-targeting and photocytotoxicity.3 Due
to the abnormal mitochondrial function of cancer cells,
mitochondrial-targeting can also lead to improved cancer
selectivity. Triphenylphosphonium (TPP) and dichloroacetate
(DCA) have been conjugated to photosensitisers as
mitochondrial-targeting tags. TPP and a Ru(II) photosensitiser
bound to human serum albumin (HSA) as a nanocarrier to form
cHSA-PEO-TPP-Ru, exhibits mitochondrial localisation, enhanced
1O2 generation, cancer accumulation and photocytotoxicity.
9
Finally, PDT can not treat advanced disseminated disease due to
the difficulty of light delivery and the limited penetration depth.
Photothermal therapy (PTT) is a new treatment for advanced
tumours, in which photosensitisers absorb NIR and release
vibrational energy (heat) to kill cancer cells, independent of
oxygen.10 However, the composition of current PTT photosensi-
tisers, mainly inorganic nanomaterials, needs to be optimised if
they are to become clinical drugs.
The introduction of light into cancer treatment can provide
precise tumour localisation of treatment and low invasiveness.
Due to the novel mechanism of action, phototherapy is not usually
cross-resistant with other cancer treatments, and thus can be a
component of combination treatments. Current new develop-
ments in the design of both light sources and photoactive agents
suggest that oncological phototherapy will have wider applica-
tions in the future.
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